Get the Stockscreener App
4.63
3.04%
-0.14
Achieve Life Sciences Inc stock is traded at $4.63, with a volume of 618.04K.
It is down -3.04% in the last 24 hours and down -9.31% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$4.77
Open:
$4.73
24h Volume:
618.04K
Relative Volume:
0.56
Market Cap:
$475.82M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-3.5758
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
-22.79%
1M Performance:
-9.31%
6M Performance:
+7.06%
1Y Performance:
+39.73%
1-Day Range:
$4.55
$4.7976
1-Week Range:
$4.55
$6.138
52-Week Range:
$2.00
$6.15
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.635 | 489.68M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
438.98 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.13 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
798.83 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.64 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.29 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2026 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences (ACHV) registers 99.04M shares for resale by investors - Stock Titan
Achieve Life Sciences Releases Q1 2026 Financial Results - AlphaStreet
Achieve Life Sciences (ACHV) Secures $180M Financing for Cytisin - GuruFocus
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Achieve Life Sciences Q1 2026 beats EPS expectations - Investing.com
Achieve Life Sciences Q1 2026: Loss Narrows 38.7% to -$0.19/Share - AlphaStreet
Achieve Life Sciences Q1 Earnings Call Highlights - MarketBeat
Achieve Life Sciences adds three executives to leadership team By Investing.com - Investing.com South Africa
ACHV: Achieve Aims for FDA Approval of Cytisinicline as New Smok - GuruFocus
How Should Investors Value Achieve Life Sciences (ACHV) After Q1 - GuruFocus
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 - Minichart
Achieve Life Sciences Q1 loss narrows more than expected - TradingView
Q1 2026 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings - ChartMill
Achieve Life Sciences Adds Director Amid Board Transitions - TipRanks
Achieve Life Sciences adds three executives to leadership team - Investing.com
ACHIEVE LIFE SCIENCES ($ACHV) Releases Q1 2026 Earnings - Quiver Quantitative
Achieve Life Sciences (NASDAQ: ACHV) posts Q1 loss, funds cytisinicline with $180M raise - Stock Titan
Achieve Life Sciences, Inc. unveils first quarter 2026 earnings and leadership update - Traders Union
Achieve Life | 8-K: Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
Achieve Life Sciences (Nasdaq: ACHV) boosts cash with $354M private placement - Stock Titan
Achieve Life Sciences, Inc. Announces Board and Executive Changes - marketscreener.com
Achieve Life Sciences Announces Senior Leadership Appointments to Drive Commercialization of Cytisinicline - Quiver Quantitative
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma - The Manila Times
Press Release: Achieve Life Sciences Strengthens Board and Commercial Leadership With Three Senior Appointments From Team Previously at Verona Pharma - Moomoo
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ... By GuruFocus - Investing.com Canada
Achieve Life Sciences Q1 2026 earnings preview - MSN
Citizens Initiates Coverage of Achieve Life Sciences (ACHV) with Market Outperform Recommendation - MSN
SEC EDGAR Submission 0001564590-19-044976 - SEC.gov
Wall Street Zen Upgrades Achieve Life Sciences (NASDAQ:ACHV) to Sell - MarketBeat
Achieve Life Sciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Number of shareholders of Achieve Life Sciences, Inc. – LS:A2QAR3 - TradingView
Franklin (NYSE: ACHV) reports 6.37M-share position, includes warrants - Stock Titan
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 - The Manila Times
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
1.93%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):